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Abstract 
Glutamate is the major excitatory neurotransmitter in the mammalian brain. Its rapid clearance after the 
release into the synaptic cleft is vital in order to avoid toxic effects and is ensured by several transmembrane 
transport proteins, so-called excitatory amino acid transporters (EAATs). Impairment of glutamate removal 
has been linked to several neurodegenerative diseases and EAATs have therefore received increased 
attention as therapeutic targets. O-benzylated L-threo-β-hydroxyaspartate derivatives have been developed 
previously as highly potent inhibitors of EAATs with TFB-TBOA ((2S,3S)-2-amino-3-((3-(4-
(trifluoromethyl)benzamido)benzyl)oxy)succinic acid) standing out as low-nanomolar inhibitor. We report 
the stereoselective synthesis of all four stereoisomers of TFB-TBOA in less than a fifth of synthetic steps 
than the published route. For the first time, the inhibitory activity and isoform selectivity of these TFB-
TBOA enantio- and diastereomers were assessed on human glutamate transporters EAAT1-3. Furthermore, 
we synthesized potent photoaffinity probes based on TFB-TBOA using our novel synthetic strategy. 
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selectivity; photoaffinity probes. 
 
Introduction 
The involvement of glutamate in electrophysiological processes in the brain was first proposed and 
later confirmed in the 1950s.1 It has been established since that the glutamatergic system regulates most of 
the excitatory activities in the central nervous system and it is estimated that 80-90% of the neurons use 
glutamate as neurotransmitter. A crucial step is the rapid termination of glutamate excitation since a high 
concentration of glutamate in the synaptic cleft, as upon release from pre-synaptic vesicles, is leading to 
excitotoxicity over time, which in turn can result in neuronal damage.2  
Rapid removal of extracellular glutamate is achieved by five selective transmembrane transport 
proteins belonging to the solute carrier (SLC) 1 family: EAAT1 (human gene SLC1A3, termed GLAST in 
rodents), EAAT2 (SLC1A2, GLT-1), EAAT3 (SLC1A1, EAAC1), EAAT4 (SLC1A6) and EAAT5 
(SLC1A7). The first three are generally expressed in the brain and play a fundamental role in the termination 
of glutamate-mediated excitation at synapses. The latter two are very tissue specific and only found in 
Purkinje cells in the cerebellum (EAAT4) and in retina (EAAT5), respectively. EAAT3 is mainly located 
on the surface of post-synaptic neurons, whereas EAAT1 and EAAT2 are expressed in astrocytes. EAAT2 
alone is responsible for the transport of >90% of extracellular glutamate into astrocytes. Not surprisingly, 
impairment of the glial glutamate transporters in particular, is leading to excitotoxic effects and death of 
neurons. In fact, several studies have linked the reduced function or expression of glutamate transporters to 
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer, Parkinson and 
Huntington disease.2,3 Thus, enhancing glutamate transport is a viable therapeutic strategy for 
neuroprotection and corresponding studies both in vitro and in vivo in a mouse model of ALS, for instance, 
-3- 
 
have provided some encouraging results.4 Addressing glutamate transporters with modulators does not only 
pose a challenge in terms of isoform selectivity and dynamic expression levels; it has very recently been 
shown for GLT-1 at least, that they are highly mobile at the surface of astrocytes, which in turn shapes 
synaptic transmission.5,6 
Several research groups have investigated the activity of small molecules, in particular L-glutamate 
(1) and L-aspartate (2) derivatives (Chart 1), to inhibit specific glutamate transporter isoforms.7 
 
Chart 1. EAAT transporter substrates L-Glu and L-Asp and inhibitors 3-5 derived thereof. 
 
Early on, threo-L-β-hydroxyaspartate ((2S,3S)-3) was discovered to inhibit glutamate transport in 
synaptosomes and later identified as EAAC1 blocker.8 Shimamoto and co-workers developed a series of 
threo-L-β-hydroxyaspartate derivatives that are the most potent inhibitors of EAAT1-3 to date. From their 
first two studies, L-TBOA ((2S,3S)-4, L-threo-β-benzyloxyaspartate) emerged as the most active compound 
(IC50 values in the low micromolar range).
9-11 L-TBOA was used in numerous neurobiological studies and, 
among other things, co-crystallized with the homologous prokaryotic aspartate transporter GltPh from 
Pyroccocus hirokoshii (PDB ID: 2NWW).12 Notably, extending the structure at the phenyl ring, as 
exemplified by the best compound TFB-TBOA ((2S,3S)-5), yielded EAAT2 and EAAT3 inhibitors with 
IC50 values in the low nanomolar range.
13 
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Using the information from GltPh crystal structures12,14 other groups have used a structure-based 
screening approach to identify conformationally constrained analogues of aspartate and glutamate in a 
virtual compound library.15 This led to the discovery of a norbornane-type aspartate derivative which 
exhibited an IC50 of 1.4 μM for EAAT2 and showed no inhibition of EAAT3. Moving away from amino 
acid scaffolds, Bunch and co-workers synthesized a library of substituted 5-oxo-5,6,7,8-tetrahydro-4H-
chromenes and identified congeners that were potent inhibitors of EAAT1 (IC50 0.43 μM for best 
compound) but displayed no noticeable inhibitory activity at EAAT2 and EAAT3.16-18 
The published asymmetric syntheses of L-TBOA ((2S,3S)-4) and TFB-TBOA ((2S,3S)-5) are rather 
elaborate (10 and 21 synthetic steps, respectively).11,19 Our goal was to establish a general and concise 
synthetic procedure to prepare derivatives of TFB-TBOA that we envision to develop into molecular probes 
for studying glutamate transporters in cells. Here, we report the synthesis of all four stereoisomers of TFB-
TBOA (5) in only four synthetic steps and their inhibitory activity at human isoforms EAAT1-3. 
Furthermore, we used our novel synthetic strategy to generate two potent photoaffinity probes based on the 
TFB-TBOA scaffold. 
 
Results and Discussion 
Chemistry 
In our retrosynthetic analysis the benzyl ether in 5 was disconnected which led to bromide 6 and the 
key intermediate β-hydroxyaspartate 3 (Scheme 1). After some literature research we envisaged to use 
asymmetric aminohydroxlyation developed by Sharpless and co-workers20-22 to install the two stereogenic 
centers in one reaction with high syn-selectivity to access the threo (2,3-syn) isomers (TBOA, Scheme 1, 
retrosynthetic path a). For the projected erythro (2,3-anti) isomers (EBOA, Scheme 1, retrosynthetic path 
b) we chose to utilize the Davis α-hydroxylation methodology23 to diastereoselectively install the 
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stereogenic centre at C-3. Thus, the projected synthetic plan would allow us to access all four stereoisomers 
of 5 in a very short four-step sequence starting either from fumarate 7 or protected aspartate 8. 
 
 
Scheme 1. Retrosynthetic analysis and synthetic strategy to access all four isomers of 5. 
 
First, dimethyl fumarate (7) was converted to the tert-butyl diester 9 in order to streamline 
deprotection conditions at the end of the synthesis (Scheme 2). Following a recently published 
modification24 of the Sharpless aminohydroxylation protocol yielded protected hydroxyaspartate 10 with 
complete diastereoselectivity (only syn isomers formed) in 65%. The major improvement of this protocol 
is the use of 4-chlorobenzoyloxycarbamate (11) instead of the commonly used N-chlorocarbamate25 that 
has to be formed in situ from tert-butyl carbamate and freshly prepared tert-butyl hypochlorite under 
aqueous basic conditions. In the presence of chiral ligand (DHQD)2PHAL the aminohydroxylation led to 
(2S,3S)-10 as major enantiomer, whereas using the pseudo-enantiomer (DHQ)2PHAL as ligand gave mainly 
(2R,3R)-10. In both cases the enantiomeric ratio (er) was determined to be 7:3 by chiral HPLC. It is 
important to run the aminohydroxylation reaction at -15°C in order to suppress formation of 1,2-diol side 
products resulting from asymmetric dihydroxylation that is also operational under the reaction conditions. 
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The free hydroxyl group of 10 was O-alkylated with bromide 626 (synthesis see Supporting Information). 
Global deprotection using TFA in chloroform led to enantioenriched isomers (2S,3S)-5 or (2R,3R)-5. By 
following the same synthetic route as shown in Scheme 2 but omitting the chiral phthalazine ligand in the 
asymmetric aminohydroxylation step we also synthesized the racemic mixture of the 2,3-syn (threo) 
isomers of 5 for biological assessment.  
 
 
Scheme 2. Synthesis of 2,3-syn isomers (threo) of 5. Reagents and conditions: (a) t-BuOH, n-BuLi, THF, 
0°C; then 7, 0°C to rt, 71%. (b) for (2S,3S)-10 (shown): OsO4, (DHQD)2PHAL, 11, H2O/MeCN, -15°C; 
then 9, H2O/MeCN, -15° to rt, 65%, er 70:30. For (2R,3R)-10 (not shown): OsO4, (DHQ)2PHAL, 11, 
H2O/MeCN, -15°C; then 9, H2O/MeCN, -15° to rt, 63%, er 69:31. (c) NaH, DMF, -15°C; then 6, -15°C to 
rt, 99% for (2S,3S)-12, 98% for (2R,3R)-12. (d) TFA, CHCl3, rt, 84% for (2S,3S)-5, quant. for (2R,3R)-5. 
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The synthesis of the two 2,3-anti (erythro) enantiomers started from enantiomerically pure N-Boc 
protected L- or D-aspartate that was first transformed into the corresponding di-tert-butyl ester 13 (Scheme 
3) in order to simplify deprotection at the end. 
 
 
Scheme 3. Synthesis of 2,3-anti isomers (erythro) of 5. Reagents and conditions: (a) CuCl, DIPC, t-BuOH; 
then 8, CH2Cl2, reflux, 79% for (S)-13, 97% for (R)-13. (b) NaHMDS, THF, -78°C; then 14, THF, -78°C, 
22% and dr 93:7 for (2S,3R)-10, 26% and dr 92:8 for (2R,3S)-10. (c) NaH, 6, DMF, -15°C to 0°C, 19% for 
(2S,3R)-12, 21% for (2R,3S)-12. (d) TFA, CHCl3, rt, 82% for (2S,3R)-5, 96% for (2R,3S)-5.  
 
Unexpectedly, this protection step failed or resulted in very low yields when employing commonly used 
conditions. A recently published protocol27 utilizing di-iso-propylcarbodiimide (DIPC), t-BuOH and CuCl 
as reagents ultimately worked best for us. The α-hydroxylation reaction developed by Davis and co-workers 
is a powerful methodology to stereoselectively install hydroxyl groups next to carbonyl functions.28 In our 
particular case, treatment of fully protected aspartate 13 with NaHMDS at low temperature generated the 
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corresponding ester enolate which was then almost exclusively attacked by the oxaziridine 14 from the 
opposite face of the N-Boc group, yielding the 2,3-anti hydroxylated product with high diastereoselectivity 
(dr 92:8-93:7). The isolated yield of the α-hydroxylated products was low and a large amount of unreacted 
starting material was usually recovered. The O-alkylation of the 2,3-anti (erythro) alcohols 10 proved much 
more troublesome as we observed epimerization and elimination at reaction temperatures above 5°C. 
Monitoring epimerization (by 1H NMR) is advisable since the separation of diastereomers 2,3-anti-12 and 
2,3-syn-12 is extremely difficult. Interestingly, once purified and isolated, the 2,3-anti isomers of 12 appear 
to be configurationally stable even at elevated temperature (60°C for 24 h in DMSO-d6). Global 
deprotection to yield the final compounds (2S,3R)-5 and (2R,3S)-5 was achieved by treatment with TFA in 
chloroform.  Notably, the 2,3-anti isomers did not epimerize under the strong acidic conditions. For the 
biological assessment we also synthesized the racemic mixture of the 2,3-anti isomers of 5 by starting from 
racemic N-Boc aspartate and following the synthetic route depicted in Scheme 3. 
The synthetic route depicted in Scheme 2 is amenable to rapidly access TFB-TBOA analogues. For 
instance, by alkylating alcohol (2S,3S)-10 with the appropriate building blocks we generated diazirine- and 
benzophenone-TFB-TBOA photoaffinity probes 15 and 16 (Chart 2), respectively (details of their synthesis 
see Supporting Information). Diazirine and benzophenone moieties appended to pharmacophores are 
commonly used for photo-crosslinking studies with proteins and can help to map the binding site of the 
pharmacophore.29,30 
 
Chart 2. Structures of EAAT photoaffinity probes 15 and 16. 
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Biological Activity 
With all four stereoisomers of 5 in hand, we next examined their ability to inhibit glutamate uptake 
into cells. To this end, HEK293 cell lines stably expressing either human EAAT1, 2 or 3 were generated 
and transport of [3H]-L-glutamate into these cells in the presence of 5 was determined using a similar assay 
set up as described previously (using 10 M L-glutamate in the transport assay).31 For all four stereoisomers 
of 5 we observed dose-dependent inhibition of [3H]-L-glutamate transport (Figure 1). 
 
Figure 1. Dose-dependent inhibition of [3H]-L-glutamate transport mediated by EAAT1 (▲), EAAT2 (■) 
or EAAT3 (●), by stereoisomers of 5. Top panels: 2,3-syn isomers (threo, TFB-TBOA), bottom panels: 
2,3-anti isomers (erythro, TFB-EBOA). Dose-inhibition curves shown are representative experiments. L-
Glutamate concentration used in the transport assay was 10 M. All data are means of 3 measurements ± 
SD. 
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Overall, the 2,3-syn (threo, TFB-TBOA) isomers of 5 are more potent inhibitors of glutamate uptake 
facilitated by EAAT1, 2 or 3 than the 2,3-anti (erythro, TFB-EBOA) isomers by one to two orders of 
magnitude (Table). This is in line with what was observed for the stereoisomers of β-benzyloxyaspartate, 
where for instance L-TBOA ((2S,3S)-4) was a more active inhibitor than L-EBOA ((2S,3R)-4).11 It is 
interesting to note, however, that the difference in inhibitory potency of the β-benzyloxyaspartate 
stereoisomers 4 is more or less pronounced depending on the glutamate transporter isoform studied; an 
observation that we have also made with our synthesized stereoisomers of 5. 
 
Table. Inhibiton of Human Glutamate Transporter-mediated [3H]-L-Glutamate Uptake by TFB-TBOA and 
TFB-EBOA Stereoisomers.a 
 compound 
IC50 (nM) 
EAAT1  EAAT2  EAAT3  
2,3-syn, threo TFB-TBOA 
commercial (S,S)-TFB-TBOA 8.2 ± 3.6 9.3 ± 1.0 248 ± 76 
synthetic TFB-TBOA, (2S,3S)-5b 20.7 ± 3.9 9.9 ± 1.3 284 ± 34 
(2R,3R)-5b 19.2 ± 4.2 12.2 ± 4.1 412 ± 86 
rac-(2RS,3RS)-5 10.1 ± 1.5 6.4 ± 1.8 228 ± 37 
2,3-anti, erythro TFB-EBOA 
(2S,3R)-5 1051 ± 97 175 ± 65 13824 ± 5007 
(2R,3S)-5 335 ± 96 181 ± 68 2399 ± 1690 
rac-(2RS,3SR)-5 619 ± 73 179 ± 88 5208 ± 2830 
 
aL-Glutamate concentration used in the transport assay was 10 M. All data are means of at least 3 
independent experiments performed in triplicate ± SD.  
bEnantioenriched, er 7:3 
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In terms of isoform selectivity, EAAT2 was inhibited most strongly by all four stereoisomers of 5, followed 
by EAAT1 and then EAAT3, for the latter of which we obtained IC50 values in the high nanomolar to low 
micromolar range.  
The IC50 values for our synthetic TFB-TBOA ((2S,3S)-5), even though only enantioenriched, were 
almost identical for EAAT2 and EAAT3 and very similar for EAAT1 compared to the values we obtained 
with commercially available (S,S)-TFB-TBOA. Furthermore, the IC50 values obtained with our assay are 
very comparable to literature values for (S,S)-TFB-TBOA, where [14C]-L-glutamate uptake into COS-1 
cells transiently expressing EAAT1, 2 or 3 gave IC50 values of 22 ± 0.4 nM, 17 ± 1 nM and 300 ± 45 nM, 
respectively.13 When comparing the enantiomers (2S,3S)-5 and (2R,3R)-5 (both enantioenriched to the same 
degree, er 7:3) it appears that (2S,3S)-5 is only twice as potent an inhibitor of EAAT3 as (2R,3R)-5, but has 
very similar inhibitory activity at EAAT1 and EAAT2 compared to its enantiomer. Interestingly, the 
racemic mixture (50:50) of both 2,3-syn (threo) enantiomers (rac-(2RS,3RS)-5) gave very similar IC50 
values compared to commercially available (S,S)-TFB-TBOA. This lack of stereoselectivity in inhibitor 
binding by EAAT1 and EAAT2 might seem unusual but is not unprecedented for transporters. Poly-specific 
binding of enantiomeric cyclic peptide inhibitors was also observed in the case of the ABC transporter P-
glycoprotein (P-gp) due to mainly hydrophobic and aromatic interactions between the inhibitor and the 
transporter.32 
The stereoselectivity in terms of inhibitor activity is more pronounced for the 2,3-anti (erythro, TFB-
EBOA) isomers of 5, in particular in the case of EAAT3; the (2R,3S)-isomer of 5 was about five times more 
active than its enantiomer (2S,3R)-5. Furthermore, IC50 values for the racemic mixture of both TFB-EBOA 
enantiomers lay between values of the two individual enantiomers. As for the 2,3-syn (threo) isomers above, 
the stereoselection of EAAT1 and EAAT2 for the 2,3-syn (erythro) isomers was weakly manifested. 
 Both photoaffinity probes 15 and 16 inhibited transport of [3H]-L-glutamate via EAAT1-3 in a dose-
dependent manner (Figure S1). Inhibition of EAAT1 was significantly stronger by 15 than 16 (IC50 0.11 ± 
0.02 M and 1.23 ± 0.29 M, respectively). Similarly, diazirine 15 was the slightly more active inhibitor 
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than 16 at EAAT2 (IC50 0.40 ± 0.03 M and 0.82 ± 0.08 M, respectively), however, for EAAT3 this was 
the opposite (15: IC50 4.03 ± 0.80 M; 16: IC50 2.11 ± 0.58 M). Overall, both photoaffinity probes are 
more potent inhibitors than the standardly used DL-TBOA (IC50 values 48.0 ± 4.1, 7.0 ± 1.1 and 8.0 ± 1.9 
M for EAAT1, EAAT2 and EAAT3, respectively).11 
 
Conclusions 
We have developed a short and concise synthesis for the preparation of all four stereoisomers of 
TFB-TBOA, a known and potent inhibitor of glutamate uptake by excitatory amino acid transporters 
EAAT1-3. Our only four-step synthetic route relies on the Sharpless asymmetric aminohydroxylation to 
access the 2,3-syn (threo) isomers, whilst we have employed the Davis asymmetric α-hydroxylation to 
prepare the 2,3-anti (erythro) isomers of TFB-TBOA. For the first time all four stereoisomers have been 
tested on human glutamate transporters EAAT1-3 and our data show that the correct relative 
stereochemistry is crucial for high inhibitory activity, with the 2,3-syn (threo) isomers being clearly more 
active than the 2,3-anti (erythro) isomers. On the other hand, the absolute stereochemistry plays a minor 
role and enantioselectivity was effectively only observed for EAAT3. This observation implies that it is 
probably not necessary to use enantiomerically pure (S,S)-TFB-TBOA for biological studies but the racemic 
mixture, that is very easily synthesized following our developed protocol, is equally potent. Following our 
synthetic strategy, two TFB-TBOA-derived photoaffinity probes have been synthesized which exhibited 
sub-micromolar to micromolar inhibitory activity at EAAT1-3 and therefore could be useful molecular 
tools for photo-crosslinking studies. Efforts to develop further EAAT molecular probes with improved 
activities are underway in our laboratory and will be reported in due course.  
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Methods 
General Procedure for the Synthesis of 2,3-syn β-hydroxyaspartates (2S,3S)-10 and (2R,3R)-
10. OsO4 (5 μmol) was added as an aqueous stock solution (61 μL of 2% OsO4 in H2O) to a stirred solution 
of either (DHQD)2PHAL (14.5 μmol, for obtaining the S,S-isomer) or (DHQ)2PHAL (for obtaining the 
R,R-isomer) and 4-chlorobenzoyloxycarbamate 11 (43.8 μmol, synthesis see Supporting Information) in 
MeCN (2.5 mL). After stirring at room temperature for 12-25 min, the yellow-brown reaction mixture was 
cooled to -15°C and a solution of fumarate 9 (43.8 mmol, synthesis see Supporting Information) in 
MeCN/H2O 4:1 (2.5 mL) was added slowly over a period of 15-45 min at -15°C. Upon addition, the color 
of the reaction mixture changed to dark green. After completed addition it was left to warm up to room 
temperature, whereupon the color changed again to pale yellow. Reaction control revealed no more product 
formation after 4 h. The reaction was quenched by addition of sat. aqueous K2S2O5 soln. (1 mL) which 
resulted in the precipitation of a fine brown powder. After addition of H2O (20 mL) and EtOAc (20 mL) 
the phases were separated and the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined 
organic layers were washed with sat. aqueous NaHCO3 soln. (2 x 15 mL) and brine (15 mL), dried over 
Na2SO4, filtered and concentrated under reduced pressure to afford the crude product. This was purified by 
flash column chromatography (silica gel, EtOAc/hexane 1:9) and gave syn-β-hydroxyaspartate as single 
diastereomer. For spectral data of (2S,3S)-10 and (2R,3R)-10 see Supporting Information. 
General Procedure for the Synthesis of 2,3-anti β-hydroxyaspartates (2S,3R)-10 and (2R,3S)-
10. A solution of N-Boc protected (S)- or (R)-aspartate diester 13 (0.87 mmol) in dry THF (30 mL) was 
cooled to -78°C and  a solution of NaHMDS in THF (1M, 2.17 mL, 2.17 mmol) was added dropwise. After 
stirring for 2 h at -78°C a solution of oxazirine 14 (1.04 mmol, synthesis see Supporting Information) in 
dry THF (6 mL) was added at -78°C to the reaction mixture. The progress of the reaction was monitored 
by TLC (silica gel, EtOAc/hexane 2:8) and was complete after 30-45 min. The reaction was quenched 
at -78°C by addition of a solution of camphorsulfonic acid (3.6 mmol) in THF (3.6 mL) and further diluted 
with EtOAc (100 mL). The organic phase was washed with aqueous HCl (10%, 100 mL), sat. aqueous 
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NaHCO3 soln. (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentration under reduced 
pressure. The diastereomeric purity of the crude products (determined by 1H NMR) was dr 92:8-94:6. The 
crude was purified twice by flash column chromatography (silica gel, first column: CH2Cl2/MeOH 99:1, 
second column EtOAc/hexane 1:9) to afford anti-β-hydroxyaspartate as single diastereomer. For spectral 
data of (2S,3R)-10 and (2R,3S)-10 see Supporting Information. 
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